Cambrooke Therapeutics (USA) is Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company develops, tests and commercializes products that are today focused on inborn errors of metabolism and intractable epilepsy. The company wa acquired in November 2017 by Ajinomoto. Co. Inc, with a 55% IRR for Seventure Partners.